左旋多巴诱导的帕金森病异动症基础研究现状与展望  

Current situation and prospect of basic studies on levodopa-induced dyskinesia in Parkinson’s disease

作　　者：王乔 孟凡刚[1] Wang Qiao;Meng Fangang(Beijing Neurosurgical Institute,Capital Medical University,Beijing 100070,China)

机构地区：[1]首都医科大学,北京市神经外科研究所,100070

出　　处：《中华实验外科杂志》2020年第9期1587-1593,共7页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(81971070);北京市医院管理局临床医学发展专项(XMLX201833)。

摘　　要：帕金森病(PD)是一种常见的神经退行性疾病,左旋多巴是PD治疗的常用药物,但长期使用该药会导致部分患者出现以舞蹈样动作为主的运动障碍,即左旋多巴诱导的异动症(LID),严重影响患者的生活质量。目前对LID的认识尚不完全,人们认为其发生发展与患者固有的黑质纹状体病变及后期药物的脉冲式刺激有关,涉及多种神经信号通路与脑网络电生理活动的改变,且不同类型的LID发生机制也存在差异。目前对LID的预防与治疗方法还不能完全满足临床需求。随着相关研究的发展,人们对突触水平、信号通路水平及基因水平的认识不断深入,该并发症的发病机制也一定会得到合理的解释,并进一步指导临床工作,造福PD患者。Parkinson’s disease(PD)is a common neurodegenerative disease,and levodopa is the commonly-used medicine.However,long-term use of levodopa may cause movement disorders including chorea in some patients,namely levodopa-induced dyskinesia(LID),which will worsen patients’quality of life.Understanding of LID is not enough at present.It is believed that the occurrence and development of LID is related to the inherent lesions of nigrostriatal and the pulsatile delivery of levodopa,involving a variety of neural signaling pathways and changes in brain network electrophysiological activities.And the mechanisms of different types of LID differ.At present,the prevention and treatment of LID cannot fully meet the clinical requirements.With the development of research on synapses,signaling pathways and genes,the pathogenesis of LID is bound to be reasonably explained,which will further guide clinical work and benefit PD patients.

关 键 词：帕金森病 左旋多巴 异动症 

分 类 号：R742.5[医药卫生—神经病学与精神病学]